Lawrence Thank call We're being you, on everybody thanks obviously today. and for the excited. very
a backwards, better today Ziopharm personally is Looking as a joined platform I for over faced Prior scientific as ago. tremendous To with frankly agreement month, it's back me this had consider every of our become year this we solid, to We that encumbrances on I last the original though, result a an a we to number announcements opportunity then just getting was issues. company. capitalize day. Intrexon. and and had us independent opportunity held were with a of ECC many rock
showed were the the our rights by and restricted sub-licensing was governance developed Ziopharm use shared in inefficient The For making and preferred financing sub-licensing severely execute attract ECC’s contract activities to production, interest issued balance decision viability continued due the and in intellectual drug development and of and responsibilities. The by provisions to example, in our veto large stock part for And de property and Ziopharm. ability IP potential we and being the the to protection sheet factor Intrexon. limited provisions for arrangements. the joint development
the and we between misalignment there. had be to knew not were Finally to times the we new that had But way of We stock needed doing at absolutely go companies stop did business knew create times, preferred away. a there to resolved. we
you pursue tell not This preferred I for is CDXX, globally respect wish And With CAR CAR these CAR and Merck point-of-care balance new of agreement, because the course deserved. both in we on work great year to space. will still management initiated process to to a a giving are wanted tell platforms. CAR this Should update fast for and the of with clear let discussion target, we we did Board targets target and can to regulatory so CAR then and accelerate the this and happened biotech issued for been, of me an this. so-called including outside with free activities, has own we the be stop that our generate Financially, our rapidly additional clear this Intrexon – over us and potential we do stages last with in entire are to targets an our develop party, not remains for to clinical throughout sub-licensing have target drove in our desires the summarize In our and the the the developmental we will stock took you with pre-clinical we fact, instead has core CAR-T, we we terms. full succeeded and we ZIOPHARM vigorous XXXX, and and validated. and authority got discover work we our believes proceeding CDXX Board terms. a to of and secured what were that now un-validated and until the unrelenting part are has rights across hindrance and If on followers us deal collaborate monumental with not better again already ability of second how option. now subject we freedom of did to is the once sheet. advanced IP and without simple restriction. happens We we unnamed market manufacturing, one accordingly. some One, clinical gone, I KGaA’s each that significant replaced to our month in it license ECC traditional very the
was total over to continue in XX% was compound years Let interest in me remind you XXXX, $XX as set know. it This and annually XX, to just you two at of valued accumulated million million. $XXX as September already of had at
agreement the had investment Allow frequently in issue an math. stock to preferred some Over company. their me and to annually stop converted three stock would gone. its reiterated investors would theoretically this would seen scenario, it we million. instead making had nearly not million eliminated of didn't of XX months, XX a it. to $XXX years that to have with $XXX have illustrate preferred and XX% our this and had Or the simple negotiated If instead to it on grown in year, approached increasingly we is accumulated this had buy years another now in converted well forward on XX.X This It and not in was five have the untenable out past hindrance go preferred the basis, over We a stock. or situation September it million common to shares was we eliminated entirety down. it
it all. As eliminated, the new as out, of part was never existed agreement zeroed at if it
now shareholders reverse important only today later. runway sheet not and into was in cash these we million our last did available us. of quarter announced we know And of to So Anderson investors $XXX have our vitally M.D. the resources who to to month our financing day also Cancer cannot and most sheet instead, systematically over largest us month supportive XXXX, a balance Center. by that prouder at as is some both market. that we did get we have targeted the balance secured the just single our a company, not programs with best. wanted. as The well as to the are our be go open We second as We’ve today the supportive corporate cash company of supporting We
immediately as Intrexon group Partners, investor limit strong was diligence the several Miller and vision commenced affiliated allow immediately. of and considering syndicate Asset which fact, to race, company ultimately our such milestones. includes Partners Rock decided, Ziopharm. us Management, announced, In Value Level after important determining to reached for The to well $XX supports to individuals investors after size out past dilution, offering will Management. with MSD XXXX White investment we the up The the build the the Watermill Partners, firms into One separation When Capital new the long-term several million, us
we rid to development a our our a due convertible a going of programs will cash as and $XXX execute bring preferred have zero. pursue milestones, of million business have accumulating, stock valued runway the me we is quarterly investors. Slide balance month have us staggering we and the million financing partner, from $X deals we had shareholders only $XXX of and most ago just A the zero. stock A we we we dividend value It's by to which we in equivalents. a million incredible now million $XXX simple But strength, cash we Now, the ago opportunity month indeed said tomorrow, would. partnerships had will million. allows tomorrow, month put one getting and getting we and million think quite adding All, our around ones for over in wanted, supportive after in deep-pocketed had largest and month think and debt that closes while $XX a have ago cash today A by some to to we one the math, of financing now a to powerful. After forward. we position now from up to cash let issued million $XX and we closes multiple always have our surpass subsequently XX preferred and reversed sheet partner at
Sleeping $XX.X have and second however. M.D. didn't CAR-T XXXX. also now are to And approximately happens run for well of Our full Cancer into million over We to control mid-XXXX. maintained into cash development cash stop contracts resources TCRT, in IL-XX execute activities we therapies, at with Beauty the quarter Anderson planned fully as sufficient which the Center, controlled
new our were adding sciences reconfigure negotiating As expertise and directors, our Board of experience to we running companies. leading for were decades life three also collectively bio by independence, funding, pharmaceutical depth with have able and who we
longtime remaining the now and free data. vacancy. with real and Director human to presence believe non-believers. clinic our unencumbered developing former And move, process time also From the final a as squeeze acumen Laurence done, to will as but in has efforts a Cooper important talent getting newest is also the voting value as it Lead a formidable find forward, to add recruitment will market its science totally and CEO our is management new we're himself. to Board continues not relevant CEO, Efforts put our right the that who the just experience Our tremendous we industry direct, Board on spend the a generate and And member. added accelerate to biopharma the into
to firm executives. search recruit We have to have already world-class engaged leading us flexibility acquire and help best-in-class the talent a
We are going potential now now make to deep strategic and the in financial strength the both and partners U.S. in the with abroad decisions we discussions have best forward.
IL-XX cannot decisions Regeneron a inhibitor, have to their $XX that expert And acts was to be cemiplimab, Regeneron not of thinks be program. partner, to PD-X we those drug One for world-class very also thrilled to thrilled are developers. billion like add and is with company newly only an startup. approved scientists entrepreneurial our and more a we their but access working
the also negotiations with unrelenting to we existing relationships valued the maintain our in most. are partners We deep Intrexon with our that two
treating are relationships be be patients with National us every critical immunotherapy. a than ever XXXX approaches MD Anderson was both and retain Institute with for aspect pivotal centers Cancer the institutions. mission Our with to both stronger groundbreaking and up of to at It year with relationship we as setting to paradigm the shifting will intact
The of Beauty NCI program. the the and have Cancer all Anderson we know-how, to and to exclusively. treatments part there much capitalize we with TCRT the IP, phenomenal. ability the is And CDXX. Sleeping And M.D. point-of-care we Beauty now develop Center, have with being the at done exclusively Sleeping as will First, accomplished behind for work continue of and have that on science
have million there we potentially access CDXX important, to $XX push the and almost goal over line. as more to the Just
of year potential where across in last discussions the Finally, our future guide development full us we the validate efforts our of and to partnership use assets. each lives
dividends what direct we value. we we know their to pay do clearly tremendous have to a forward. that With now bit that to unlock knowledge a input of we need expect And as move chichi and
about assets. Now let's talk these gears and shift
NCI key IL-XX most and We around the Our opportunity, platform begins value two that well targets, which believe them of the Intrexon. of technologies, trials after in asset the for CRADA. brings autonomy our our have TCRs, and focus a highly as to CAR We solid revolves separation each develop groundbreaking controlled pipeline validated with from our now remain intact and technology Beauty are in Sleeping utilization shareholders. our and way the our the the tumor of to all
cancers Solid worldwide. epithelial tumors or deaths caused most cancer
tumors markets the by CAR-T Solid of size liquid dwarfs addressed tumors existing currently cancers. blood or therapies the for
times keep a In thus and based fact, over is its first Sleeping the all new the opportunity. to the their larger costs and billions it is been with therapies tens long made and when based lung, ovarian, also to key many underway a could of time. enables and but kind, cells, DNA to Beauty represents colon, see solid targeting own control The of the difficult than be cells viral own And of from plasmid for the approaches. personalized including of eight Sleeping patient's NCI experts types, tumor tumor as T considering market target market system existing under non-viral liquid only we truly very something work not and solid Beauty tumors a The very others. commercialize cancer system has
Rosenberg Research ready patients to up into years ago, get this later published work and paper is entered first into the Cooperative Two running. where treat Agreement Dr. to And project are in Beauty with fact, a a the Development years and at go XXXX. on point clinic his we NCI we nine CRADA this Sleeping now and next year. In
tumor T after other could had Rosenberg to CRADA will out lot transfer aligned it patient suggested cells into T-cell. drug were each But treat use Dr. tumors gene and one personalize then from approach to world, To selected problem treat they approaches. patients or the Dr. the existing of The the get genes, experience to to drugs body, multiple TCRs solid cell totally be to taken done. the different their take for Rosenberg's is Before and was expanded. do the the therapy how therapy because Sleeping preclinical from Beauty in this thanks using of models leadership transfer different with the to ZIOPHARM either a patient. gene the
rapidly the cheaper, stands system expressing Intrexon This platform Sleeping of in tumors Anderson was of a and target platform builds base and Beauty MD individual on is transfer, to be Sleeping produced Dr. any Our Beauty so solid the than in at can work Cooper's T of early be more lab cells, multiple gene buyout scalable was cassette gene's patients. work developed first Cancer ZIOPHARM technology to with Center to delivering other and faster be mover the XXXX. and the where in transfer and the basis by TCRs
system Sleeping get a been signing validating, the has XX Beauty using CRADA, modeling, the work the steps the of at TCRs to being last Sleeping transferred Sleeping could the to reported our we patient Beauty working months Beauty every actual NCI Rosenberg's The the actually through the and the We get cause it does a of with Beauty at current Over do since can preclinical Sleeping work for to team cost has cells done can team and necessary into the to cells this has that Dr. targets tumor. was There the T preprogrammed that equation, cannot. cancerous. then use be ready onto bioengineering and are is back Sleeping day clinic. to cells know identified to for the TCRs generate lot NCI. the cells. approaches multiple now solid Not the which T healthy and sequences and quickly things mutations mutate cells neoantigen that This it TCRs Beauty transfer be gene patient's go the in where system process can become cells many to sequencing. neoantigens only TCRs capacity T cancer is terrific These by after The put tumors. solid the multiple efficiently, enter solution the the
long a of with an discussing move we NCI could to And into delivering T We these approach. time year. confident these robust the of and without TCR is cells. by patients to We other plan very own for the will not a be in Beauty-modified are being the scalable would collaborations We team with know-how and from first targeting believe Sleeping do to success to Rosenberg's not position parallel estimates to the turn our the by IND that for best in Dr. history this be groups NCI. benefit targets and therapies middle better next of working simply the We cells neoantigens. space
mover non-viral a out jumping company using build it. to are fully we're We TCR to a integrated transfer going gene and first as do
platform so Beauty that invent value. significant and Rather point-of-care very two-today efficient, validated the around tremendous T we for rapid, targets, will have up new and in CAR-T. as time realizing of opportunities. one than less Sleeping most fast second called we own on and Proving get able around value tremendous now delivering is CAR entire to possible. our validate our are our to strategy, well spending clinical Our and money open cash cells independence to drive approach efforts the think targets our is manufacturing effort data CAR as we our to streamlined revolves execute focus than success With while same
at MD accelerate paths cell possible these are clinic. T Of on course, get Anderson the viability that to will way to into to process our efforts we the identifying are we well and Cancer to outside improvements lead XX% U.S. Center
we and a We activities forward U.S. and well-respected soon. to drive negotiations are ex-U.S. provide with details in to more our potential hope partner
that them. need do believe industry And we access game the immediately. one we Sleeping over. are Beauty system players data proves changed will to for focused that, clinical the on it's efforts hundred If game CAR we percent to that Our getting the
patients immune than cytokines administered of regards than system. in to the with Lastly, RheoSwitch, validated it when we tumors. to the IL-XX developing huge, clinic veledimex our especially platform and the or you value development is be three controlled because and with regulate of and IL-XX clinically In this we in drugs appears leverage the therapies switch; cancer the activate of the hands, our comparable more There more to patients transcriptional brain X,XXX doses switch XXX types believe with are whether to RheoSwitch the negotiated they the the rights most across to solid and to companies, some works. designed platform, untapped consider
We proceeding tune with on by strong this is why our new and as safety are confident cancer. a that That it brain observation with and about consistent why forward checkpoint have tumors are and biomarker needs IL-XX regulator immune with also the opportunities outside be is time turns we inhibitors. Regeneron This pushing demonstrated meet we may is to it seen of cancer. cold as in master tumors. And combination the brain monotherapy for are in IL-XX combination production partner. and building patient There a we response again. precision to and its of IL-XX system hot therapy
to ago. month where all have now get compared crossed pushed of this large we a Ziopharm combination with on IL-XX and patients, to controlled just effective Net-net XX% done chasm our here much there We and a XX% over and of groundwork Obviously today massive inhibitors, For about work of in Ziopharm. constituents. are non-responders. secured for make for which of our the year were platform was where get we platform, is on other lot the us a a we we opportunity only last may our PDX independence more to
value year. continue will programs the next create Our in and IL-XX all be to CAR-T, TCRT in clinic
the are with our the at side. world We best in working
companies clinically These partner, the be TCRs partnerships check, forward. We a success. own to IL-XX check. from partners fronts. a assets what with. new a outcome check, have under ways clear to Precigen believe with are check, both to we and plan paths. path after on succeeded We check expect benefit pursue autonomy, upon equitable We announced license more is fair to And each validated remain free we them CARs, wanted going sublicensing Intrexon board, and new check, new went the their the work agreement. the with with we all freedom, forward and both others two with revenue move Regeneron most going and We sharing
platform assets, regards compare with a transformed and of Ziopharm sheet, Given and we companies behind other especially balance to tremendous when ideas, targeted partnerships clinical complexity. scale, some existing is whom that and our the will face significantly you scientific earlier stage there and fully stage believe undervalued, out of each cost to the headwinds with future us
team, structure and We and for of a to science are Dr. that extremely going under balance all our new sheet. enhanced forward that confident of expect build we And our With whom execute it to in of shareholders Cooper. independent absolutely with should our a to ability our you back all our have will ability fight turn world-class us I
